DE69637096T2 - Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen - Google Patents
Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen Download PDFInfo
- Publication number
- DE69637096T2 DE69637096T2 DE69637096T DE69637096T DE69637096T2 DE 69637096 T2 DE69637096 T2 DE 69637096T2 DE 69637096 T DE69637096 T DE 69637096T DE 69637096 T DE69637096 T DE 69637096T DE 69637096 T2 DE69637096 T2 DE 69637096T2
- Authority
- DE
- Germany
- Prior art keywords
- propargyl
- aminoindan
- medicament according
- pharmaceutical composition
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 11
- 239000003814 drug Substances 0.000 claims description 24
- RUOKEQAAGRXIBM-UHFFFAOYSA-N n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(NCC#C)CCC2=C1 RUOKEQAAGRXIBM-UHFFFAOYSA-N 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 150000001298 alcohols Chemical class 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- XBQBIMOUVWKNGG-UHFFFAOYSA-N 1-prop-2-ynyl-2,3-dihydroinden-1-amine Chemical compound C1=CC=C2C(N)(CC#C)CCC2=C1 XBQBIMOUVWKNGG-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 15
- 102000010909 Monoamine Oxidase Human genes 0.000 description 4
- 108010062431 Monoamine oxidase Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000005038 alkynylalkyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- -1 flavorings Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid Fuels And Fuel-Associated Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11535795 | 1995-09-20 | ||
| IL11535795A IL115357A (en) | 1995-09-20 | 1995-09-20 | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| PCT/IL1996/000115 WO1997012583A2 (en) | 1995-09-20 | 1996-09-18 | Stable compositions containing n-propargyl-1-aminoindan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69637096D1 DE69637096D1 (de) | 2007-07-05 |
| DE69637096T2 true DE69637096T2 (de) | 2008-01-31 |
Family
ID=11068003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69637096T Expired - Lifetime DE69637096T2 (de) | 1995-09-20 | 1996-09-18 | Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6126968A (OSRAM) |
| EP (1) | EP0858328B1 (OSRAM) |
| JP (1) | JP4108750B2 (OSRAM) |
| AT (1) | ATE362755T1 (OSRAM) |
| AU (1) | AU728524B2 (OSRAM) |
| CA (1) | CA2232310C (OSRAM) |
| DE (1) | DE69637096T2 (OSRAM) |
| DK (1) | DK0858328T3 (OSRAM) |
| ES (1) | ES2287940T3 (OSRAM) |
| HU (1) | HU225859B1 (OSRAM) |
| IL (1) | IL115357A (OSRAM) |
| PT (1) | PT858328E (OSRAM) |
| WO (1) | WO1997012583A2 (OSRAM) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| CA2387394C (en) | 1999-10-27 | 2009-08-18 | Teva Pharmaceutical Industries, Ltd. | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
| PT1567152E (pt) * | 2002-11-15 | 2013-10-03 | Teva Pharma | Uso de rasagilina com riluzol para tratar a esclerose lateral amiotrófica |
| GB2411355B (en) | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
| CA2574925A1 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms including rasagiline |
| CA2587295A1 (en) * | 2004-11-10 | 2006-05-18 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
| US8367105B2 (en) | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
| NZ555470A (en) * | 2004-11-24 | 2011-02-25 | Teva Pharma | Rasagiline orally disintegrating compositions |
| US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| ES2420404T3 (es) * | 2005-02-17 | 2013-08-23 | Teva Pharmaceutical Industries Ltd. | Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple |
| KR20170023211A (ko) * | 2005-02-23 | 2017-03-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 함량 균일성이 개선된 라사길린 제형 |
| CN101622225B (zh) | 2005-11-17 | 2015-04-15 | 泰华制药工业有限公司 | 炔丙基氨基茚分离方法 |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| ES2632638T3 (es) | 2005-12-09 | 2017-09-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva |
| ES2551481T3 (es) | 2006-02-21 | 2015-11-19 | Teva Pharmaceutical Industries, Ltd. | Uso de rasagilina para el tratamiento de atrofia multisistémica |
| TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
| NZ571591A (en) | 2006-04-03 | 2011-09-30 | Teva Pharma | Use of rasagiline for the treatment of restless legs syndrome |
| DE202006020710U1 (de) | 2006-05-09 | 2009-12-31 | Teva Pharmaceutical Industries Ltd. | Zusammensetzungen mit Rosiglitazonmaleat |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| WO2008076315A1 (en) | 2006-12-14 | 2008-06-26 | Teva Pharmaceutical Industries, Ltd. | Tannate salt of rasagiline |
| HRP20110980T1 (hr) * | 2006-12-14 | 2012-02-29 | Teva Pharmaceutical Industries Ltd. | Kristalna kruta rasagilinska baza |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| US20090247537A1 (en) * | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
| EP2271612B1 (en) * | 2008-03-31 | 2016-08-10 | Actavis Group PTC EHF | Rasagiline mesylate particles and process for the preparation thereof |
| CA2727022A1 (en) * | 2008-06-13 | 2009-12-17 | Teva Pharmaceutical Industries Ltd. | Rasagiline for parkinson's disease modification |
| JP2011524907A (ja) | 2008-06-19 | 2011-09-08 | テバ ファーマシューティカル インダストリーズ リミティド | 固体ラサギリン塩基を調製および乾燥する方法 |
| EP2299993A4 (en) * | 2008-06-19 | 2014-08-20 | Teva Pharma | PROCESS FOR PURIFYING THE BASE OF RASAGILINE |
| US20100189788A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
| EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| US20120122993A1 (en) | 2009-03-05 | 2012-05-17 | Sandoz Ag | Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-(1r)-, methanesulfonate |
| DK2451771T3 (da) | 2009-07-09 | 2014-09-08 | Ratiopharm Gmbh | Salte af rasagilin og farmaceutiske fremstillingsmåder heraf |
| CN102048717B (zh) * | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| WO2011087791A1 (en) | 2009-12-22 | 2011-07-21 | Teva Pharmaceutical Industries Ltd. | 3-keto-n-propargyl-1-aminoindan |
| CA2793571C (en) | 2010-04-30 | 2015-10-13 | Teikoku Pharma Usa, Inc. | Propynylaminoindan transdermal compositions |
| EP2389927A1 (en) | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of rasagiline |
| CA2806740A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| US8691872B2 (en) | 2010-07-27 | 2014-04-08 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| WO2012129429A2 (en) | 2011-03-24 | 2012-09-27 | Teikoku Pharma Usa, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| JP2014534196A (ja) | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン |
| EP2766007A4 (en) * | 2011-10-10 | 2015-03-25 | Teva Pharma | RASAGILINE CITRAMIDE |
| EP2766004A4 (en) | 2011-10-10 | 2015-04-22 | Teva Pharma | R (+) - N-methyl-propargyl-aminoindan |
| US9913812B2 (en) | 2011-11-09 | 2018-03-13 | Teikoku Pharma Usa, Inc. | Methods for the treatment of skin neoplasms |
| DE102012000786A1 (de) | 2012-01-18 | 2013-07-18 | Stada Arzneimittel Ag | Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin |
| EP2827848B1 (en) | 2012-03-21 | 2016-04-27 | Synthon BV | Stabilized pharmaceutical compositions comprising rasagiline salts |
| WO2013175493A1 (en) | 2012-04-09 | 2013-11-28 | Cadila Healthcare Limited | Stable oral pharmaceutical compositions |
| BR112015003451A2 (pt) | 2012-08-17 | 2017-07-04 | Teva Pharma | formulação parentérica de rasagilina |
| KR101856515B1 (ko) | 2012-11-02 | 2018-05-10 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 프로피닐아미노인단 경피 조성물 |
| ES2502140T1 (es) * | 2013-02-06 | 2014-10-02 | Galenicum Health S.L. | Comprimidos de liberación inmediata de rasagilina hemitartrato |
| ES2524865T1 (es) * | 2013-02-06 | 2014-12-15 | Galenicum Health S.L. | Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata |
| CN115400090A (zh) * | 2022-10-09 | 2022-11-29 | 北京新领先医药科技发展有限公司 | 一种雷沙吉兰的口崩片组合物及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1187017A (en) * | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
| GB8909793D0 (en) * | 1989-04-28 | 1989-06-14 | Beecham Group Plc | Pharmaceutical formulation |
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| CA2039742A1 (en) * | 1990-04-23 | 1991-10-24 | Andrew B. Dennis | Tablet composition and method for problem pharmaceutical materials |
| IL112819A (en) * | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| IL112779A (en) * | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
| WO1996026720A1 (en) * | 1995-03-02 | 1996-09-06 | R.P. Scherer Limited | Pharmaceutical compositions comprising monoamine oxidase b inhibitors |
-
1995
- 1995-09-20 IL IL11535795A patent/IL115357A/xx not_active IP Right Cessation
-
1996
- 1996-09-18 AT AT96930344T patent/ATE362755T1/de active
- 1996-09-18 HU HU9802999A patent/HU225859B1/hu unknown
- 1996-09-18 DK DK96930344T patent/DK0858328T3/da active
- 1996-09-18 AU AU69427/96A patent/AU728524B2/en not_active Expired
- 1996-09-18 ES ES96930344T patent/ES2287940T3/es not_active Expired - Lifetime
- 1996-09-18 CA CA002232310A patent/CA2232310C/en not_active Expired - Lifetime
- 1996-09-18 JP JP51411997A patent/JP4108750B2/ja not_active Expired - Lifetime
- 1996-09-18 DE DE69637096T patent/DE69637096T2/de not_active Expired - Lifetime
- 1996-09-18 US US09/043,475 patent/US6126968A/en not_active Expired - Lifetime
- 1996-09-18 EP EP96930344A patent/EP0858328B1/en not_active Expired - Lifetime
- 1996-09-18 PT PT96930344T patent/PT858328E/pt unknown
- 1996-09-18 WO PCT/IL1996/000115 patent/WO1997012583A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69637096D1 (de) | 2007-07-05 |
| HU225859B1 (en) | 2007-11-28 |
| JP4108750B2 (ja) | 2008-06-25 |
| DK0858328T3 (da) | 2007-09-03 |
| EP0858328B1 (en) | 2007-05-23 |
| AU728524B2 (en) | 2001-01-11 |
| EP0858328A2 (en) | 1998-08-19 |
| HUP9802999A2 (hu) | 1999-04-28 |
| IL115357A0 (en) | 1995-12-31 |
| PT858328E (pt) | 2007-08-20 |
| IL115357A (en) | 2000-01-31 |
| EP0858328A4 (en) | 2001-07-11 |
| CA2232310A1 (en) | 1997-04-10 |
| US6126968A (en) | 2000-10-03 |
| JPH11512736A (ja) | 1999-11-02 |
| CA2232310C (en) | 2008-01-08 |
| ES2287940T3 (es) | 2007-12-16 |
| AU6942796A (en) | 1997-04-28 |
| WO1997012583A3 (en) | 1997-06-05 |
| ATE362755T1 (de) | 2007-06-15 |
| WO1997012583A2 (en) | 1997-04-10 |
| HUP9802999A3 (en) | 1999-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69637096T2 (de) | Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen | |
| DE69623634T2 (de) | Pharmazeutische zusammensetzung von l-dopa ethyl ester | |
| EP2477660B1 (de) | Pharmazeutische zusammensetzung mit den wirkstoffen metformin und sitagliptin oder vildagliptin | |
| DE69432121T2 (de) | Bupropion enthaltendes stabilisiertes arzneimittel | |
| DE69435095T2 (de) | Neue Behandlungsmethoden durch Verwendung von Phenethylaminderivaten | |
| DE69833684T2 (de) | Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen | |
| EP2037891B1 (de) | Tablette enthaltend candesartan cilexetil | |
| DE60020501T3 (de) | Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe | |
| DE60210139T2 (de) | Pharmazeutische zusammensetzungen enthaltend tegaserod | |
| DE4315525B4 (de) | Pharmazeutische Zusammensetzung | |
| DE69520292T2 (de) | Pharmazeutische zubereitung zur direktverpressung | |
| DE19740983A1 (de) | Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten | |
| DE3150557C2 (OSRAM) | ||
| DE19813661A1 (de) | Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron | |
| DE69209916T2 (de) | Oral anzuwendende Arzneimittel Dapiprazol enthaltend | |
| DE69717253T2 (de) | Captopriltabletten | |
| DE102005060377A1 (de) | Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung | |
| DE69909163T2 (de) | Eine feste Präparation und dessen Herstellungsverfahren | |
| DE3005029C2 (de) | Antihypertensive pharmazeutische Zubereitungen | |
| DE10393805T5 (de) | Pharmazeutische Formulierungen, die ß-2-Adrenorezeptor-Agonisten und Xantine enthalten | |
| AU771490B2 (en) | Stable compositions containing N-propargyl-1-aminoidan | |
| EP1408943B1 (de) | Arzneimittelformulierung enthaltend einen ltb4 antagonisten und einen netzmittel | |
| WO2006084684A1 (de) | Pharmazeutische zusammensetzungen nebivolo und ein hydrophiles polymer | |
| US6121328A (en) | Racemic propranolol | |
| DE602006000402T2 (de) | Stabile Zubereitung enthaltend eine feuchtigkeitsemphindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |